These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20176578)

  • 21. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
    Joseph J; Rodvold KA
    Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
    Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
    Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
    Kelly HC; Hutchison M; Haworth SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():35-41. PubMed ID: 8543497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
    Matthews SJ; Lancaster JW
    Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-performance liquid chromatographic assay for meropenem in serum.
    Elkhaïli H; Niedergang S; Pompei D; Linger L; Leveque D; Jehl F
    J Chromatogr B Biomed Appl; 1996 Nov; 686(1):19-26. PubMed ID: 8953188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
    Toya T; Nannya Y; Narukawa K; Ichikawa M; Kurokawa M
    Jpn J Infect Dis; 2012; 65(3):228-32. PubMed ID: 22627304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers.
    Ong W; Nowak P; Cu Y; Schopf L; Bourassa J; Enlow E; Moskowitz SM; Chen H
    Pharm Res; 2016 Mar; 33(3):563-72. PubMed ID: 26508478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of the stability of meropenem in intravenous mixtures.
    Takasu Y; Yoshida M; Tange M; Asahara K; Uchida T
    Chem Pharm Bull (Tokyo); 2015; 63(4):248-54. PubMed ID: 25832020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity.
    Mendez A; Chagastelles P; Palma E; Nardi N; Schapoval E
    Int J Pharm; 2008 Feb; 350(1-2):95-102. PubMed ID: 17904314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural comparison of 1 beta-methylcarbapenem, carbapenem and penem: NMR studies and theoretical calculations.
    Nishimura T; Igarashi J; Sasaki A; Sunagawa M
    Bioorg Med Chem; 1998 Apr; 6(4):367-75. PubMed ID: 9597181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM; Engel AE; Glass D; Li C
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and clinical tolerability of FCE 22101, a new penem antibiotic, in healthy volunteers after a single i.m. administration.
    Hitzenberger G; Strolin Benedetti M; Jannuzzo MG; Silvestri S; Moro E; Frigerio E; Sassella D
    J Chemother; 1989 Jul; 1(4 Suppl):513-4. PubMed ID: 16312509
    [No Abstract]   [Full Text] [Related]  

  • 35. New developments in carbapenems.
    Kattan JN; Villegas MV; Quinn JP
    Clin Microbiol Infect; 2008 Dec; 14(12):1102-11. PubMed ID: 19076841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of doripenem.
    Sahm D
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostatic penetration of meropenem after intravenous administration in patients undergoing transurethral resection of the prostate.
    Yamada Y; Ikawa K; Nakamura K; Mitsui K; Narushima M; Hibi H; Ikeda K; Morikawa N; Honda N
    J Chemother; 2011 Jun; 23(3):179-80. PubMed ID: 21742590
    [No Abstract]   [Full Text] [Related]  

  • 38. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
    Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
    J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly].
    Okimoto N; Ishiga M; Nanba F; Kibayashi T; Kishimoto M; Kurihara T; Honda Y; Asaoka N; Tamada S
    Nihon Kokyuki Gakkai Zasshi; 2009 Jul; 47(7):553-7. PubMed ID: 19637794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetics of carbapenems].
    Suchánková H; Rychlíčková J; Urbánek K
    Klin Mikrobiol Infekc Lek; 2012 Jun; 18(3):68-74. PubMed ID: 22786828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.